Commentary on “Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience.” Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W. Department of Surgery (Urology), McGill University, Quebec, Canada: BJU Int 2012;110(9):1317-23 [Epub 2012 Apr 13]

Autor: Kamat, Ashish M.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations July 2013 31(5):717-718

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms.

Autor: Shih L; Department of Medicine, University of Washington, Seattle, WA, USA., Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Schonhoff K; Department of Medicine, University of Washington, Seattle, WA, USA., Shaw C; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Appelbaum J; Department of Medicine, University of Washington, Seattle, WA, USA., Halpern AB; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Becker PS; Department of Medicine, University of Washington, Seattle, WA, USA.; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA., Walter RB; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA., Estey E; Department of Medicine, University of Washington, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Percival ME; Department of Medicine, University of Washington, Seattle, WA, USA. mperciva@uw.edu.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. mperciva@uw.edu.

Publikováno v: Leukemia [Leukemia] 2023 Sep; Vol. 37 (9), pp. 1912-1914. Date of Electronic Publication: 2023 Jul 31.

Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?

Autor: Estey E; Division of Hematology, University of Washington, Seattle, WA, USA. eestey@uw.edu.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. eestey@uw.edu., Karp JE; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Emadi A; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Othus M; Public Health Division and SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gale RP; Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, UK.

Publikováno v: Leukemia [Leukemia] 2020 Mar; Vol. 34 (3), pp. 671-681. Date of Electronic Publication: 2020 Jan 08.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Autor: Estey, E H¹

Publikováno v: Leukemia (08876924). Sep2013, Vol. 27 Issue 9, p1803-1812. 10p. 2 Charts, 4 Graphs.

New study-designs to address the clinical complexity of acute myeloid leukemia.

Autor: Estey E; Divisions of Hematology and Clinical Research, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA. eestey@uw.edu., Othus M; M. Othus - Public Health Division and SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gale RP; R. P. Gale - Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.

Publikováno v: Leukemia [Leukemia] 2019 Mar; Vol. 33 (3), pp. 567-569. Date of Electronic Publication: 2019 Jan 22.